These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25844810)

  • 1. Improving environmental risk assessment of human pharmaceuticals.
    Ågerstrand M; Berg C; Björlenius B; Breitholtz M; Brunström B; Fick J; Gunnarsson L; Larsson DG; Sumpter JP; Tysklind M; Rudén C
    Environ Sci Technol; 2015 May; 49(9):5336-45. PubMed ID: 25844810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated testing and intelligent assessment-new challenges under REACH.
    Ahlers J; Stock F; Werschkun B
    Environ Sci Pollut Res Int; 2008 Oct; 15(7):565-72. PubMed ID: 18818964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 Oct; 135(3):231-7. PubMed ID: 12270681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 May; 131(1-2):137-43. PubMed ID: 11988366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients.
    Carlsson C; Johansson AK; Alvan G; Bergman K; Kühler T
    Sci Total Environ; 2006 Jul; 364(1-3):67-87. PubMed ID: 16257037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process.
    Laenge R; Steger-Hartmann T; Schweinfurth H
    Regul Toxicol Pharmacol; 2006 Aug; 45(3):223-8. PubMed ID: 16716476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceuticals in the environment: scientific evidence of risks and its regulation.
    Küster A; Adler N
    Philos Trans R Soc Lond B Biol Sci; 2014 Nov; 369(1656):. PubMed ID: 25405974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBT assessment and prioritization of contaminants of emerging concern: Pharmaceuticals.
    Sangion A; Gramatica P
    Environ Res; 2016 May; 147():297-306. PubMed ID: 26921826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeating history: pharmaceuticals in the environment.
    Ankley GT; Brooks BW; Huggett DB; Sumpter JP
    Environ Sci Technol; 2007 Dec; 41(24):8211-7. PubMed ID: 18200843
    [No Abstract]   [Full Text] [Related]  

  • 10. Human pharmaceutical products in the environment - the "problem" in perspective.
    Taylor D; Senac T
    Chemosphere; 2014 Nov; 115():95-9. PubMed ID: 24525259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the accuracy and consistency of the Swedish environmental classification and information system for pharmaceuticals.
    Agerstrand M; Rudén C
    Sci Total Environ; 2010 May; 408(11):2327-39. PubMed ID: 20206966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the regulatory environmental risk assessment of human pharmaceuticals: Required changes in the new legislation.
    Gildemeister D; Moermond CTA; Berg C; Bergstrom U; Bielská L; Evandri MG; Franceschin M; Kolar B; Montforts MHMM; Vaculik C
    Regul Toxicol Pharmacol; 2023 Aug; 142():105437. PubMed ID: 37354938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated approach for prioritizing pharmaceuticals found in the environment for risk assessment, monitoring and advanced research.
    Caldwell DJ; Mastrocco F; Margiotta-Casaluci L; Brooks BW
    Chemosphere; 2014 Nov; 115():4-12. PubMed ID: 24636702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International scientists' priorities for research on pharmaceutical and personal care products in the environment.
    Rudd MA; Ankley GT; Boxall AB; Brooks BW
    Integr Environ Assess Manag; 2014 Oct; 10(4):576-87. PubMed ID: 24954797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.
    Ortiz de García S; Pinto GP; García-Encina PA; Irusta Mata RI
    J Environ Manage; 2013 Nov; 129():384-97. PubMed ID: 23995140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting and evaluation criteria as means towards a transparent use of ecotoxicity data for environmental risk assessment of pharmaceuticals.
    Ågerstrand M; Küster A; Bachmann J; Breitholtz M; Ebert I; Rechenberg B; Rudén C
    Environ Pollut; 2011 Oct; 159(10):2487-92. PubMed ID: 21763042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceuticals and personal care products: research needs for the next decade.
    Brooks BW; Huggett DB; Boxall AB
    Environ Toxicol Chem; 2009 Dec; 28(12):2469-72. PubMed ID: 19908931
    [No Abstract]   [Full Text] [Related]  

  • 18. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international conference on "Pharmaceutical products in the environment: is there a problem?" in the framework of the EU PHARMAS Project.
    Roig B; Thomas O
    Chemosphere; 2014 Nov; 115():1-3. PubMed ID: 24594485
    [No Abstract]   [Full Text] [Related]  

  • 20. The challenge: do pharmaceuticals present a risk to the environment, and what needs to be done to answer the question?
    Sumpter JP
    Environ Toxicol Chem; 2014 Sep; 33(9):1915. PubMed ID: 25138028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.